These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 16140322

  • 1. Genetic modification of the heart: transgenic modification of cardiac lipid and carbohydrate utilization.
    Hartil K, Charron MJ.
    J Mol Cell Cardiol; 2005 Oct; 39(4):581-93. PubMed ID: 16140322
    [Abstract] [Full Text] [Related]

  • 2. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy.
    Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE.
    Circ Res; 2005 Feb 04; 96(2):225-33. PubMed ID: 15618539
    [Abstract] [Full Text] [Related]

  • 3. The heart requires glycerol as an energy substrate through aquaporin 7, a glycerol facilitator.
    Hibuse T, Maeda N, Nakatsuji H, Tochino Y, Fujita K, Kihara S, Funahashi T, Shimomura I.
    Cardiovasc Res; 2009 Jul 01; 83(1):34-41. PubMed ID: 19297367
    [Abstract] [Full Text] [Related]

  • 4. Diabetes-related metabolic perturbations in cardiac myocyte.
    Feuvray D, Darmellah A.
    Diabetes Metab; 2008 Feb 01; 34 Suppl 1():S3-9. PubMed ID: 18358420
    [Abstract] [Full Text] [Related]

  • 5. Diabetic cardiomyopathy.
    Feuvray D.
    Arch Mal Coeur Vaiss; 2004 Mar 01; 97(3):261-5. PubMed ID: 15106750
    [Abstract] [Full Text] [Related]

  • 6. Targets for modulation of fatty acid oxidation in the heart.
    Lopaschuk GD.
    Curr Opin Investig Drugs; 2004 Mar 01; 5(3):290-4. PubMed ID: 15083595
    [Abstract] [Full Text] [Related]

  • 7. Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect?
    Ritchie RH, Delbridge LM.
    Clin Exp Pharmacol Physiol; 2006 Mar 01; 33(1-2):159-66. PubMed ID: 16445716
    [Abstract] [Full Text] [Related]

  • 8. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice.
    de Brouwer KF, Degens H, Aartsen WM, Lindhout M, Bitsch NJ, Gilde AJ, Willemsen PH, Janssen BJ, van der Vusse GJ, van Bilsen M.
    J Mol Cell Cardiol; 2006 Jun 01; 40(6):838-45. PubMed ID: 16697005
    [Abstract] [Full Text] [Related]

  • 9. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts.
    Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R, Larsson NG.
    Proc Natl Acad Sci U S A; 2004 Mar 02; 101(9):3136-41. PubMed ID: 14978272
    [Abstract] [Full Text] [Related]

  • 10. Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy.
    Khairallah M, Khairallah R, Young ME, Dyck JR, Petrof BJ, Des Rosiers C.
    J Mol Cell Cardiol; 2007 Aug 02; 43(2):119-29. PubMed ID: 17583724
    [Abstract] [Full Text] [Related]

  • 11. Constitutive SIRT1 overexpression impairs mitochondria and reduces cardiac function in mice.
    Kawashima T, Inuzuka Y, Okuda J, Kato T, Niizuma S, Tamaki Y, Iwanaga Y, Kawamoto A, Narazaki M, Matsuda T, Adachi S, Takemura G, Kita T, Kimura T, Shioi T.
    J Mol Cell Cardiol; 2011 Dec 02; 51(6):1026-36. PubMed ID: 21964378
    [Abstract] [Full Text] [Related]

  • 12. Carbohydrate-enriched diet impairs cardiac performance by decreasing the utilization of fatty acid and glucose.
    Pôrto LC, Savergnini SS, de Castro CH, Mario EG, Ferreira AV, Santos SH, Andrade SP, Santos RA, de Almeida AP, Botion LM.
    Ther Adv Cardiovasc Dis; 2011 Feb 02; 5(1):11-22. PubMed ID: 21282201
    [Abstract] [Full Text] [Related]

  • 13. Aerobic capacity-dependent differences in cardiac gene expression.
    Bye A, Langaas M, Høydal MA, Kemi OJ, Heinrich G, Koch LG, Britton SL, Najjar SM, Ellingsen Ø, Wisløff U.
    Physiol Genomics; 2008 Mar 14; 33(1):100-9. PubMed ID: 18171719
    [Abstract] [Full Text] [Related]

  • 14. [Modifications in myocardial energy metabolism in diabetic patients]].
    Grynberg A.
    Diabetes Metab; 2001 Nov 14; 27(5 Pt 2):S12-9. PubMed ID: 11910980
    [Abstract] [Full Text] [Related]

  • 15. Lipids in the heart: a source of fuel and a source of toxins.
    Park TS, Yamashita H, Blaner WS, Goldberg IJ.
    Curr Opin Lipidol; 2007 Jun 14; 18(3):277-82. PubMed ID: 17495601
    [Abstract] [Full Text] [Related]

  • 16. Alterations in energy metabolism in cardiomyopathies.
    Taha M, Lopaschuk GD.
    Ann Med; 2007 Jun 14; 39(8):594-607. PubMed ID: 17934906
    [Abstract] [Full Text] [Related]

  • 17. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.
    Lopaschuk GD.
    Semin Cardiothorac Vasc Anesth; 2006 Sep 14; 10(3):228-30. PubMed ID: 16959756
    [Abstract] [Full Text] [Related]

  • 18. Lack of myoglobin causes a switch in cardiac substrate selection.
    Flögel U, Laussmann T, Gödecke A, Abanador N, Schäfers M, Fingas CD, Metzger S, Levkau B, Jacoby C, Schrader J.
    Circ Res; 2005 Apr 29; 96(8):e68-75. PubMed ID: 15817884
    [Abstract] [Full Text] [Related]

  • 19. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway.
    Pellieux C, Aasum E, Larsen TS, Montessuit C, Papageorgiou I, Pedrazzini T, Lerch R.
    J Mol Cell Cardiol; 2006 Sep 29; 41(3):459-66. PubMed ID: 16859699
    [Abstract] [Full Text] [Related]

  • 20. Acute effect of antidiabetic 1,4-dihydropyridine compound cerebrocrast on cardiac function and glucose metabolism in the isolated, perfused normal rat heart.
    Briede J, Stivrina M, Vigante B, Stoldere D, Duburs G.
    Cell Biochem Funct; 2008 Sep 29; 26(2):238-45. PubMed ID: 17990288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.